Pfiz­er-backed Me­di­ar Ther­a­peu­tics ropes in an­oth­er Big Phar­ma in­vestor

A biotech cen­tered on treat­ing fi­bro­sis — born out of Mass Gen­er­al and Brigham and Women’s Hos­pi­tal — has re­ceived a fi­nan­cial boost.

Ac­cord­ing to an SEC fil­ing, the com­pa­ny has raised $31,761,186 in its lat­est fund­ing round, which in­cludes 17 in­vestors. The fil­ing lists six names at­tached to the com­pa­ny, in­clud­ing Mered­ith Fish­er, a part­ner at Mass Gen­er­al Brigham Ven­tures and Me­di­ar’s act­ing CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER